RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
28.85
+1.06 (3.81%)
Nov 14, 2025, 4:00 PM EST - Market closed
RAPT Therapeutics Employees
RAPT Therapeutics had 68 employees as of December 31, 2024. The number of employees decreased by 63 or -48.09% compared to the previous year.
Employees
68
Change (1Y)
-63
Growth (1Y)
-48.09%
Revenue / Employee
n/a
Profits / Employee
-$1,553,485
Market Cap
799.46M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68 | -63 | -48.09% |
| Dec 31, 2023 | 131 | 34 | 35.05% |
| Dec 31, 2022 | 97 | 16 | 19.75% |
| Dec 31, 2021 | 81 | 13 | 19.12% |
| Dec 31, 2020 | 68 | 1 | 1.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RAPT News
- 3 hours ago - RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices - Seeking Alpha
- 9 days ago - RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 10 days ago - RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies - GlobeNewsWire
- 24 days ago - RAPT Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 24 days ago - RAPT Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 25 days ago - RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript - Seeking Alpha
- 26 days ago - CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz